AI Tool ‘Mirai‘ Shows Promise in Predicting Interval Breast Cancer Risk
Table of Contents
A new artificial intelligence tool, called Mirai, demonstrates the potential to significantly improve breast cancer detection rates by identifying women at higher risk of developing interval cancer – cancer that develops between regular screening mammograms. The findings, stemming from a study conducted by researchers at the University of Cambridge and published by the Radiological Society of North America (RSNA), offer a pathway toward more personalized and effective screening programs.
The study analyzed over 134,000 mammograms from women aged 50 to 70 participating in the British triennial screening program, ultimately identifying 524 cases of interval cancer.
AI Outperforms Customary Methods in Risk Assessment
The deep learning algorithm was able to retrospectively predict 42% of interval cancers within the 20% of women identified as having the highest risk scores. This represents a substantial advancement over existing prediction tools, according to the research. “Mirai” proved especially effective in predicting cancers diagnosed within the frist year following a negative mammogram.
However, the algorithm’s performance was somewhat diminished in women with extremely dense breast tissue, a known challenge in mammographic interpretation. Despite this limitation, the tool’s overall accuracy signals a major step forward in proactive cancer detection.
Personalized Screening: A Potential Future for Breast Cancer Care
The research team proposes that women identified as high-risk through the Mirai algorithm could benefit from additional diagnostic measures. These could include complementary imaging techniques – such as ultrasound or MRI – or a reduction in the time between screenings. This targeted approach could lead to earlier detection of aggressive tumors and, ultimately, a reduction in breast cancer mortality.
According to the World Health Organization (WHO), breast cancer is the most prevalent cancer among women globally, accounting for 12% of all new cancer cases annually. The integration of artificial intelligence into screening programs is increasingly viewed as a crucial strategy for optimizing healthcare resources and tailoring testing to individual risk profiles, particularly within public health systems facing high demand.
The development of tools like Mirai underscores the growing role of AI in revolutionizing healthcare, offering the potential to move beyond one-size-fits-all approaches and deliver more precise, proactive, and ultimately life-saving care.
Here’s a substantive news report answering the “Why, who, What, and How” questions:
Why: researchers developed and tested the AI tool, Mirai, to address the challenge of interval cancers – those detected between scheduled mammograms – which contribute significantly to breast cancer mortality. Existing risk assessment tools were proving insufficient.
Who: The study was conducted by researchers at the University of Cambridge and published by the Radiological Society of North America (RSNA). The study involved over 134,000 women aged 50-70 participating in the British triennial screening program.
What: The AI tool, Mirai, a deep learning algorithm, demonstrated the ability to retrospectively predict 42% of interval cancers within the 20% of women identified as highest risk. It was particularly effective at predicting cancers diagnosed within the first year after a negative mammogram. While performance was reduced in women with extremely dense breast tissue, the overall results represent a significant improvement over current methods.
How did it end? The study concluded that Mirai shows promise for personalized breast cancer screening. Researchers suggest high-risk women identified by the algorithm could benefit from supplemental imaging
